Hana Biosciences Obtains NASDAQ National Market Listing Approval; Hana Biosciences Shares to Trade Under Symbol HNAB on the NAS
2006年4月11日 - 8:03PM
ビジネスワイヤ(英語)
Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on
advancing cancer care, received approval of its application to list
its common shares on the NASDAQ National Market. Hana's common
shares will begin trading on NASDAQ on Monday, April 17, 2006 under
the symbol HNAB. The trading of Hana's shares on the American Stock
Exchange will cease on the close of business on Thursday, April 13,
2006. "Reaching a NASDAQ National Market listing is another
important step forward in the development of Hana," said John
Iparraguirre, Vice President and Chief Financial Officer, Hana
Biosciences. "We are excited about this important milestone and
believe that current and future shareholders will benefit from the
enhanced profile this listing provides Hana." About Hana
Biosciences Hana Biosciences, Inc. (AMEX:HBX) is a South San
Francisco, CA-based biopharmaceutical company that acquires,
develops, and commercializes innovative products to advance cancer
care. The company is committed to creating value by building a
world-class team, accelerating the development of lead product
candidates, expanding its pipeline by being the alliance partner of
choice, and nurturing a unique company culture. Additional
information on Hana Biosciences can be found at
www.hanabiosciences.com. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Hana's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual
outcomes and results to differ materially from these statements.
Among other things, there can be no assurances that any of Hana's
development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates,
the risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates, and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-K for the year ended Dec. 31,
2005. Hana assumes no obligation to update these statements, except
as required by law.
Hana Biosciences (AMEX:HBX)
過去 株価チャート
から 5 2024 まで 6 2024
Hana Biosciences (AMEX:HBX)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Hana Biosciences (アメリカ証券取引所): 0 recent articles
その他のHana Biosciences, Inc.ニュース記事